Drotrecogin alfa (activated) treatment in severe sepsis: a "journal club" review of the global ENHANCE trial.
Farmer
J Christopher
JC
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D020300:Intracranial Hemorrhages / Q000139:chemically induced*; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012107:Research Design; D018570:Risk Assessment; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated